In terms of OS rates, the analysis showed that women with CD44+/CD24- had a poor prognosis but a lower scale compared to the CD44-/CD24- phenotype [36]. Furthermore, the heterogeneity in BCSCs has been playing an important role in tumor features such as differentiation, vascular invasion, tumorigenesis, and metastatic potential [39]. This evidence concerns the gene CD44 and neoplasm.